1 Towards estimating true cholera burden: a systematic review and meta-

2 analysis of Vibrio cholerae positivity

- 3
- 4 Running title: Estimating Vibrio cholerae positivity
- 5
- 6 Kirsten E. Wiens^{1,2}, Hanmeng Xu¹, Kaiyue Zou¹, John Mwaba^{3,4}, Justin Lessler^{1,5,6}, Espoir B.
- 7 Malembaka^{1,7}, Maya N. Demby¹, Godfrey Bwire⁸, Firdausi Qadri⁹, Elizabeth C. Lee¹, Andrew S.
- 8 Azman¹
- 9
- ¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns
- 11 Hopkins University, Baltimore, USA
- 12 ² Department of Epidemiology and Biostatistics, College of Public Health, Temple University,
- 13 Philadelphia, USA
- 14 ³Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia
- ⁴Department of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka,
- 16 Zambia
- ⁵ Department of Epidemiology, Gillings School of Global Public Health, University of North
- 18 Carolina at Chapel Hill, Chapel Hill, USA
- ⁶ Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, USA
- ⁷ Center for Tropical Diseases and Global Health (CTDGH), Université Catholique de Bukavu,
- 21 Bukavu, Democratic Republic of the Congo
- ⁸ Division of Public Health Emergency Preparedness and Response, Ministry of Health,
- 23 Kampala, Uganda
- ⁹ Infectious Diseases Division, International Centre for Diarrhoeal Disease Research
- 25 Bangladesh (icddr,b), Dhaka, Bangladesh

26 Corresponding author

- 27 Andrew S. Azman, PhD
- 28 Associate Scientist
- 29 Department of Epidemiology
- 30 Johns Hopkins Bloomberg School of Public Health
- 31 615 N. Wolfe Street
- 32 Baltimore, MD 21205
- 33 <u>azman@jhu.edu</u>
- 34
- 35 Keywords
- 36 cholera, Vibrio cholerae, diagnostic test, suspected cholera, confirmed cholera

37

39 Abstract

40 Background: Cholera surveillance relies on clinical diagnosis of acute watery diarrhea. 41 Suspected cholera case definitions have high sensitivity but low specificity, challenging our 42 ability to characterize cholera burden and epidemiology. Our objective was to estimate the 43 proportion of clinically suspected cholera that are true Vibrio cholerae infections and identify 44 factors that explain variation in positivity. 45 46 Methods: We conducted a systematic review of studies from 2000-2023 that tested ≥10 47 suspected cholera cases for V. cholerae O1/O139 using culture, PCR and/or a rapid diagnostic 48 test. We searched PubMed, Embase, Scopus, and Google Scholar on October 16, 2021 and

updated the search on April 19, 2023. We estimated diagnostic test sensitivity and specificity
using a latent class meta-analysis. We estimated *V. cholerae* positivity using a random-effects
meta-analysis, adjusting for test performance.

52

53 Findings: We included 119 studies from 30 countries. V. cholerae positivity was lower in studies 54 with representative sampling and lower minimum ages in suspected case definitions. After 55 adjusting for test performance, on average 52% (95% Credible Interval: 24%, 80%) of 56 suspected cases represented true V. cholerae infections. After adjusting for test performance 57 and study methodology, odds of a suspected case having a true infection were 5.71 (Odds ratio 58 95% Credible Interval: 1.53, 15.43) times higher when surveillance was initiated in response to 59 an outbreak than in non-outbreak settings. Variation across studies was high and a limitation of 60 our approach and the resolution of the data was that we were unable to explain all the 61 heterogeneity with study-level attributes, including diagnostic test used, setting, and case 62 definitions.

63

| 64 | Conclusions: In this study, we found that burden estimates based on suspected cases alone | | |
|----|--|--|--|
| 65 | may overestimate the incidence of medically attended cholera by twofold. However, accounting | | |
| 66 | for cases missed by traditional clinical surveillance is key to unbiased cholera burden estimates. | | |
| 67 | Given the substantial variability in positivity between settings, extrapolations from suspected to | | |
| 68 | confirmed cases, which is necessary to estimate cholera incidence rates without exhaustive | | |
| 69 | testing, should be based on local data. | | |
| 70 | | | |
| 71 | Funding for this study was provided by the Bill and Melinda Gates Foundation and the National | | |
| 72 | Institute of Allergy and Infectious Disease. | | |
| 73 | | | |
| 74 | Author Summary | | |
| 75 | Why was this study done? | | |
| 76 | Cholera surveillance typically relies on the clinical diagnosis of acute watery diarrhea | | |
| 77 | (i.e., "suspected cholera"), but this definition has a low specificity for cholera. | | |
| 78 | • Our goal was to estimate the proportion of suspected cholera cases that are true Vibrio | | |
| 79 | cholerae infections and identify factors that contribute to variation in observed positivity. | | |
| 80 | What did the researchers do and find? | | |
| 81 | We conducted a systematic review of studies from 2000-2023 that tested suspected | | |
| 82 | cholera cases for V. cholerae infection using one of three different laboratory tests. | | |
| 83 | • We included 119 studies from 30 countries and found that, on average, half of suspected | | |
| 84 | cholera cases represented true V. cholerae infections, after accounting for laboratory | | |
| 85 | test accuracy. | | |
| 86 | • We also found high variability between studies and that the odds of a suspected case | | |
| 87 | being a true infection were higher during outbreaks compared to non-outbreak settings. | | |

88 What do these findings mean?

| 89 | • | Our findings suggest that burden estimates based solely on suspected cases may |
|----|---|--|
| 90 | | overestimate the incidence of medically attended cholera by twofold. |
| 91 | • | A limitation of our approach was that we couldn't account for cases missed by clinical |
| 92 | | surveillance, which is crucial for unbiased overall cholera burden estimates and an |
| 93 | | important area for future work. |
| 94 | • | The high variability across studies suggests also that local testing data should be used |
| 95 | | to inform assumptions about positivity when exhaustive testing is not feasible. |

96

97 Introduction

98 Current estimates of cholera burden rely on clinical diagnosis of individuals with acute 99 watery diarrhea (i.e., suspected cholera cases) [1,2]. It is unclear how many Vibrio cholerae 100 O1/O139 (serogroups that cause current epidemics) infections get missed due to mild 101 symptoms and other barriers to care-seeking or how many get overcounted due to non-specific 102 suspected case definitions. In Bangladesh, previous studies estimated that asymptomatic and 103 unreported infections account for at least half of V. cholerae infections [3-5]. Meanwhile, the 104 proportion of suspected cholera cases that represent laboratory-confirmed infections varies 105 widely between studies, from 6% of those tested during routine surveillance in Bangladesh [6] 106 to 72% of those tested during the initial phase of the 2017 outbreak in Yemen [7]. 107 This wide variation in positivity may be caused by differences between sites in V. 108 cholerae epidemiology [8], epidemiology of non-cholera diseases causing the same clinical 109 symptoms [9–12], and variations in diagnostic tests and case definitions [13–15]. Typical 110 suspected cholera case definitions have been shown to have high sensitivity but low specificity

- 111 [14] for detecting true cholera, and can vary by location across seasons [13]. Culture-based
- 112 methods or PCR are the gold standards to confirm cholera in clinical samples and generally

have high specificity. Lateral flow rapid diagnostic tests (RDT) may also be used and can be as
sensitive as PCR [16]. Although recommended by the Global Task Force on Cholera Control
(GTFCC) [17], systematic microbiological confirmation in surveillance is not always
implemented, particularly during outbreaks when resources are limited [8]. To our knowledge—
based on a literature review and discussion with experts—no study had yet systematically
synthesized these data to estimate overall *V. cholerae* positivity and identify sources of this
variation.

120 Understanding V. cholerae positivity among clinical cases could provide insights needed 121 to improve laboratory testing strategies and allow for better estimates of cholera burden and 122 risk, which are often used to allocate cholera resources, including oral cholera vaccines. 123 Starting in 2023, the GTFCC has recommended using a combination of suspected cholera 124 incidence, persistence, mortality, and cholera test positivity data across multiple years to identify 125 priority areas for multisectoral interventions [18], which is particularly relevant in cholera 126 endemic areas. As described above, the cholera positivity data are often not available. We 127 sought to address this knowledge gap by modeling the relationship between clinically suspected 128 and laboratory confirmed cholera. Specifically, we aimed to estimate the proportion of 129 suspected cholera cases that represent true V. cholerae O1/O139 infections and identify factors 130 that explain variability in positivity across settings.

131

132 Methods

133 <u>Terminology</u>

We focused on *V. cholerae* O1 and O139 because these are the serogroups that are responsible for the current 7th pandemic and the only ones known to lead to large outbreaks in humans [19]. These are also the serogroups that are targeted by each of the commonly used *V. cholerae* diagnostic tests (culture, PCR, RDT). Throughout this manuscript, we refer to the proportion of suspected cholera cases that represent true *V. cholerae* O1/O139 infections as "*V*.

cholerae positivity" or "cholera positivity". In addition, since the available data did not allow us to
evaluate the performance of multiple RDTs, we refer to RDT as any rapid diagnostic test for *V*. *cholerae* O1/O139 and do not distinguishing between different RDT manufacturers or whether
the RDT is enriched/direct swab RDT or stool RDT.

143

144 Systematic review

145 We searched PubMed, Embase, Scopus, Google Scholar and medRxiv on October 16, 146 2021 using search provided in the Supplementary Methods. We updated PubMed, Embase, and 147 Scopus searches on April 19, 2023. We included studies that: 1) collected human samples, 2) 148 reported the number of suspected and confirmed cholera cases in the sampling frame, 3) used 149 culture, PCR, and/or RDT to test suspected cases for cholera, and 4) had at least one 150 suspected case sample collected on or after January 1, 2000 to reflect contemporary patterns in 151 cholera positivity. We excluded studies that: 1) used a case definition not specific for suspected 152 cholera (i.e., we accepted non-bloody watery diarrhea, acute watery diarrhea, or simply 153 suspected cholera but not diarrhea, acute diarrhea, or acute gastroenteritis), 2) sampled only 154 special populations (i.e., people living with HIV or cancer), 3) selected suspected cases based 155 on epidemiological link to other cases or environmental sources, 4) tested fewer than 10 156 suspected cases, 5) were reported in languages other than English, French, Spanish, and 157 Chinese (languages our study team had proficiency in). We did not exclude studies based on 158 study type or sampling method. Although we originally included pre-prints in our screening and 159 extracted one pre-print, we excluded this study at the time of the updated search because the 160 published version of the manuscript no longer included positivity data.

161 Titles, abstracts, and full texts were uploaded to Covidence, a web-based screening tool 162 (https://www.covidence.org/), and were assessed independently by two of the reviewers (ASA, 163 ECL, HX, KEW, KZ, MND) for inclusion. Conflicts were resolved either by a third reviewer or 164 through consensus/discussion. Data were extracted from included studies in a shared

165 spreadsheet (Supplementary Data 1) by a single reviewer. The key extracted items included 166 study timeframe and location, surveillance type (routine, outbreak, post-vaccination, or hybrid), 167 case definition of suspected cholera (including age constraint and whether dehydrated or 168 hospitalized, if provided), test method(s), sampling strategy for the test (all suspected cases, 169 systematic or random sampling, convenience sampling, or unreported), number of tested and 170 confirmed suspected cases, among other sample characteristics, if included. If only the 171 proportion positive and total number tested were reported, the number of confirmed cholera 172 cases was calculated by hand and rounded to the nearest whole number. If the surveillance 173 contained multiple timeframes, tested samples with multiple tests, or reported stratified results, 174 we extracted the data separately into different rows in the spreadsheet.

175 To identify overlapping samples, we manually reviewed all studies with overlapping 176 timeframes by country. We excluded studies that had shorter timeframes, fewer suspected 177 cases tested, less representative sampling methods, fewer confirmation tests, or reported 178 positive results by two tests but did not disaggregate. Within studies, when suspected and 179 confirmed cases were stratified multiple ways, we included the stratification by surveillance type 180 if available, followed by age, antibiotic use, dehydration status, year, geography, or sex, in that 181 order. When studies used multiple RDTs, we included results for Crystal VC (Arkray Healthcare 182 Pvt. Ltd, Gujarat, India) and direct rapid tests (as opposed to rapid tests performed after an 183 enrichment step) because these were the most common.

To identify any mistakes and ensure quality of the extracted data, we performed data quality checks using a series of automated functions in R to identify implausible values (e.g., start date of study after end date, more cases positive than tested, lower age limit larger than upper age limit) and missing required data. If impossible or missing values were found, the entire extraction was double checked for accuracy and corrected by a single reviewer.

To assess whether different studies used methodologies that may have biased our
 results, we plotted cholera positivity in the raw data by 1) diagnostic test used, 2) sampling

191 method quality, and 3) suspected cholera case definition. In addition, we plotted the relationship 192 between cholera positivity in the raw data and 1) estimated suspected cholera incidence [2], 2) 193 the proportion of cases severely dehydrated, and 3) the proportion on antibiotics. We quantified 194 the correlation between these variables using Spearman's rank correlation coefficient using the 195 spearman.ci function of the RVAideMemoire package in R [20]. Since these continuous variables 196 were only available in a subset of studies, we did not adjust for them in final analyses. All data 197 visualization was conducted using the ggplot2 package in R [21]. 198 This study is reported as per the Preferred Reporting Items for Systematic Reviews and 199 Meta-Analyses (PRISMA) guideline (S1 Checklist). The review was not pre-registered, and a

200 formal public protocol was not prepared, although all study methods can be found in the

- 201 manuscript and supporting material.
- 202

203 Data analysis

204 Estimating sensitivity and specificity of cholera confirmation tests

205 We constructed a latent-class model to assess sensitivity and specificity of culture, PCR, 206 and RDT, assuming none had perfect performance. We fit a hierarchical conditional 207 dependence model, similar to that proposed by Wang et al., which takes into account potential 208 pairwise dependence between the tests that could occur if the tests have reduced performance 209 for similar reasons [22]. We performed inference in a Bayesian framework using Just Another 210 Gibbs Sampler (JAGS) through the rjags package in R [23,24]. We pooled estimates across four 211 published studies that reported cholera confirmation results for all three test methods [16,25-212 27]. 213 We used flat prior distributions on sensitivity and specificity of each test with a lower

bound set based on plausible values from the literature [15,16,25–27] (Table S1). We assumed
that culture had lower sensitivity than PCR and RDT because it depends on successful growth
of viable *V. cholerae* in the laboratory. We assumed that RDT had lower specificity than culture

and PCR because it may have cross-reactivity with other antigens in the stool or defects that
lead to false positive results. For each prior, we selected a wider range than had been reported
in previous studies to allow for greater variation. We ran 4 chains of 100,000 iterations and
assessed convergence through visual inspection of traceplots and with the Gelman-Rubin R-hat
statistic.

- 222
- 223

23 Estimating V. cholerae positivity and sources of heterogeneity

224 We pooled estimates of V. cholerae positivity across all studies using a generalized 225 linear model with a study level random intercept, which allowed us to adjust for sensitivity and 226 specificity of the diagnostic tests as well as examine the contributions of study methodology 227 (i.e., whether the study used low vs. high quality sampling, and whether or not the study set a 228 minimum age in the suspected cholera case definition) and setting (whether surveillance was 229 routine or post-vaccination vs. initiated in response to an outbreak) on variation in positivity. To 230 estimate the proportion positive, overall and by strata, we marginalized over study-level random 231 effects. See Supplementary Methods for the full statistical model. We performed inference in a 232 Bayesian framework using CmdStanR version 0.5.2 as an interface to Stan for R [24,28]. We 233 additionally performed a sensitivity analysis where we shifted the prior set on the global 234 intercept (see Supplementary Methods). The odds of a suspected cholera case having a true V. 235 cholerae infection given each covariate were calculated as odds ratios by taking the mean and 236 95% credible interval of 8000 draws from the posterior distribution of each covariate's 237 exponentiated coefficient. Odds ratios with 95% credible intervals that did not cross the value 1 238 were considered statistically significant.

To estimate the proportion of the variance in positivity attributable to true differences
 between studies, beyond simple sampling error, we calculated the l² statistic [29] as

$$I^2 = \frac{\tau^2}{\tau^2 + v}$$

242 where τ^2 was between-study heterogeneity or the variance of the random effect by observation.

243 We calculated the within-study variance, v, [30] as:

$$v = \frac{(k-1)\sum_{i}^{l}\omega_{i}}{(\sum_{i}^{i}\omega_{i})^{2} - \sum_{i}^{i}\omega_{i}^{2}}$$

where *k* was the number of studies or observations included in the meta-analysis, and $\omega_i = 1/v_i$ where v_i was the variance of the proportion positive by culture, PCR or RDT within each study/observation. When multiple tests were used in a study, we used the maximum variance estimate across the tests.

248

249 Data availability

All extracted and model input data as well as analytical code are available at

251 <u>https://github.com/HopkinsIDD/cholera_positivity</u>. This study was approved by the Johns

252 Hopkins University Institutional Review Board and Temple University Institutional Review Board.

253

254 Results

255 Study characteristics

256 We identified 131 studies that met our inclusion criteria (Figure 1). Of these, 119 studies 257 contained non-overlapping samples and were included in our analysis dataset [6,7,9,10,12–

258 14,16,25–27,31–131] and 12 were excluded from analysis due to overlaps [8,11,132–141]

(Figure 1). Of the 119 studies included in our analysis dataset, one reported data for more than one sampling method [7], one for both outbreak and non-outbreak surveillance [37], and one for outbreak and non-outbreak surveillance in six different countries [13]. We defined each of these as separate entries in the dataset for a total of 132 observations.

The non-overlapping observations in our analysis dataset came from 30 countries and were reported at different geographic levels, including the country level (n=16 observations) and first (n=25), second (n=66), and third administrative levels (n=25) (Figure S1). Twelve studies

266 reported data for multiple administrative units and three reported across multiple administrative 267 divisions within a country; the numbers above reflect the largest administrative division reported 268 per observation. Data were collected from 1992 through 2022 with most observations from 269 studies that completed sampling during 2015—2022 (n=53 observations), followed by 2010— 270 2014 (n=32), 2005—2009 (n=21), and 1997—2004 (n=17) (Figure S2). Nine studies were 271 missing sampling end dates. Most studies were conducted in South Asia and West, Central, and 272 East Africa, with additional studies from Haiti, Yemen, Iraq, Iran, Laos, Vietnam, Papua New 273 Guinea, Algeria, and the Philippines (Figure S1).

274 Most of the observations were from surveillance studies (93/132, 70.5%), followed by 275 diagnostic test accuracy studies (28/132, 21.2%) and vaccine effectiveness studies (10/132, 276 7.6%) (Table 1). Twenty-eight percent (37/132) used high-guality sampling methods (i.e., tested 277 all suspected cases, a random sample, or systematically selected every nth suspected case), 278 while the remaining 72% (95/132) used convenience sampling or did not report the sampling 279 approach (Table 1). Even though most studies did not include V. cholerae positivity 280 disaggregated by individual-level characteristics, 24.2% (32/132) reported the proportion of 281 suspected cases under age five, 8.3% (11/132) reported the proportion severely dehydrated, 282 7.6% (10/132) reported the proportion on antibiotics, and one study reported all three (Table 283 S2).

284

285 <u>V. cholerae positivity in unadjusted data</u>

We found that reported *V. cholerae* positivity varied greatly across studies with an interquartile range (IQR) of 30% to 60% (N = 165 observations of positivity; 25 of the 131 observations had positivity results for multiple tests) (Table 1). As expected, positivity varied by diagnostic test used with a median positivity of 36% by culture (IQR, 27% to 55%; N = 121), 37% by PCR (IQR, 34% to 55%; N = 11), and 49% by RDT (IQR, 38% to 67%; N = 33), with substantial overlap between distributions (Figure 2A). Positivity was higher across studies that

292 used low quality or convenience sampling methods (median of 43%; N = 117; IQR, 33% to 293 62%) compared to those that used high quality or representative sampling (median of 35%; 294 IQR, 14% to 51%) (Figure 2B). Positivity increased with higher minimum ages in suspected 295 cholera case definitions (Figure 2C), and we found a modest negative correlation between 296 positivity and the proportion of suspected cases under five years old (Spearman r = -0.60; 95%) 297 Confidence Interval (CI): -0.81, -0.32; p < 0.001) (Figure S3A).

298 Unadjusted positivity was higher when surveillance was initiated in response to an 299 outbreak (median of 47%: IQR, 33% to 66%; N = 80) compared to situations where surveillance 300 was routine or post-vaccination (median of 35%; IQR 17% to 49%; N = 85) (Figure 2D). We 301 found limited evidence for differences in positivity by the 2010-2016 estimated mean annual 302 suspected case incidence rate in countries where these estimates were available (Figure S3B, 303 [2]).

304 We found a modest positive correlation between positivity and the proportion of 305 suspected cases severely dehydrated (Spearman r = 0.64; 95% CI: 0.22, 0.90; p = 0.001) 306 (Figure S3C). While not statistically significant, we found a weak negative correlation between 307 positivity and the proportion of suspected cases that had received antibiotics prior to testing (Spearman r = -0.46; 95% CI: -0.83, 0.09; p = 0.07) (Figure S3D). 308

309

310 Adjusted underlying V. cholerae positivity

311 Since different imperfect diagnostic tests were used to confirm V. cholerae O1/O139, we 312 adjusted positivity estimates from each study to account for test performance. To estimate the 313 average performance of each type of diagnostic test, we pooled estimates of sensitivity and 314 specificity across four studies that reported detailed results for all three tests (see Methods). 315 This included data from Bangladesh [27], South Sudan [16], Kenya [25], and Zambia [26]. We 316 estimated an average sensitivity of 82.0% (95% Credible Interval (CrI): 37.5, 98.7) and 317 specificity of 94.3% (95% Crl: 81.5, 99.6) for culture, an average sensitivity of 85.1% (95% Crl:

53.6%, 98.9%) and specificity of 94.2 (95% Crl: 81.8, 99.7) for PCR, and an average sensitivity
of 90.4% (95% Crl: 55.2, 99.5) and specificity of 88.9% (95% Crl: 54.9, 99.4) for RDT (Figure
320 3A, Table S3).

After adjusting for diagnostic test performance, we estimated that 53% (95% CrI: 24%, 80%) of suspected cases tested were true *V. cholerae* O1/O139 infections across all studies (Figure 3, Figure S4, Table S4). These estimates remained similar in sensitivity analysis with an alternative prior distribution (Table S4).

325 With additional adjustments for study methodology (i.e., sampling guality and whether an 326 age minimum was set in suspected case definition), we estimated that V. cholerae positivity for 327 studies with high quality sampling methods was 46% (95% Crl: 19%, 76%) when no age 328 restriction was used and 68% (95% Crl: 33%, 98%) when a minimum age (typically 1 or 5 years 329 old) was incorporated into the case definition (Figure 3, Table S4). After adjusting for sampling 330 guality and whether or not surveillance was initiated in response to a cholera outbreak, we 331 estimated that V. cholerae positivity for studies with high quality sampling methods was 42% 332 (95% Crl: 12%, 77%) in non-outbreak settings and 78% (95% Crl: 40%, 99%) in outbreak 333 settings (Figure 3, Table S4).

We found substantial heterogeneity between studies ($l^2 = >99.99\%$ (95% CrI: >99.99%, >99.99%; $\Box^2 = 0.96$ (95% CrI: 0.94, 0.98)) (Figure 4). Adjusted underlying positivity rates ranged from 0.008% (95% CrI: 0.0004%, 0.04%) for a high-quality study conducted during routine surveillance in Bangladesh to 99.8% (95% CrI: 98.7%, 100.0%) for a 'low-quality' study conducted during a cholera outbreak in Uganda (Figure 4).

339

340 Factors associated with variation in *V. cholerae* positivity

We then examined factors that could explain variation in *V. cholerae* positivity. After
adjusting for test performance, sampling quality, and outbreak setting, we found that setting any

minimum age in the case definition (i.e., 1, 2, 5 or 10) was associated with 2.33 (95% CrI: 0.54,
6.40) times higher odds of a suspected cholera case having a true infection (Table S5).
We estimated that the odds of a suspected cholera case having a true *V. cholerae*O1/O139 infection were 5.71 (95% CrI: 1.53, 15.43) times higher when surveillance was
initiated in response to a cholera outbreak compared to non-outbreak surveillance, after
adjusting for test performance, sampling quality, and case definition (Table S5).

349

350 Discussion

351 Here we estimated that on average half of medically attended suspected cholera cases 352 represent true V. cholerae O1/O139 infections. We found that V. cholerae positivity was higher 353 when a minimum age was set in case definitions and when surveillance was initiated in 354 response to an outbreak. Additionally, we found substantial heterogeneity in V. cholerae 355 positivity between studies, so that simply multiplying the number of suspected cholera case 356 counts by this global proportion positive to estimate the true number of cases will not be 357 appropriate in most settings. To our knowledge, this is the first study to systematically 358 synthesize data globally to estimate overall V. cholerae positivity and examine factors that 359 contribute to variation in positivity.

360 A remaining question is why only about half of medically attended suspected cholera 361 cases represent true infections. It is possible that we overestimated test sensitivity and have not 362 fully accounted for false negatives; unfortunately, this is difficult to evaluate without a gold 363 standard diagnostic test. A portion of the remaining suspected cases could also be infections 364 with other enteric pathogens, especially those with similar transmission modes as cholera that 365 may have outbreaks or high levels of endemic transmission concurrently. For example, in Uvira, 366 Democratic Republic of the Congo, 36% of suspected cholera cases were positive for 367 Enterotoxigenic Escherichia coli and 28% for Cryptosporidium [10]. In rural Bangladesh, the 368 majority of acute watery diarrhea in children under 18 months was attributable to rotavirus, while

older children were more often infected with *V. cholerae* [12]. In Haiti, 64% of acute watery
diarrhea cases tested positive for *V. cholerae* O1, 4% for rotavirus, and <1% for Shigella and
Salmonella, though rotavirus positivity was higher among children under five [11]. Thus, the
relative contribution of non-cholera watery diarrhea varies with age distribution and other
location-specific drivers of enteric infections.

374 One of the limitations of this study was that we could not account for all potential drivers 375 of V. cholerae positivity, which contributed to the large heterogeneity we found between studies. 376 In addition, V. cholerae positivity may be highest in the early stages of an outbreak [7,9,131]. 377 but we could not account for this given the temporal resolution of our dataset. However, a 378 strength of our approach is that we pooled estimates from studies across diverse geographies. 379 time periods, and epidemiological contexts. A further potential limitation is that, without a gold 380 standard diagnostic test, sensitivity and specificity estimates may be biased if the tests are less 381 sensitive and/or specific for shared reasons. The hierarchical conditional dependence model we 382 used accounted for this pairwise dependence and increased uncertainty around our estimates 383 accordingly. This approach also allowed us to pool test performance estimates across studies 384 from four countries. Thus, to our knowledge, we adjusted our estimates for test sensitivity and 385 specificity using the best generic estimates available. Still, we likely overestimated sensitivity of 386 culture for settings where samples had to be sent to a reference lab. Variation in the timing of 387 tests in relation to when sample was taken could mean that one sensitivity and specificity 388 estimate per diagnostic method is not appropriate. For example, a recent study in Haiti found 389 that stool culture had a sensitivity of 33% during the waning phase of the 2018-2019 cholera 390 outbreak [142], which is much lower than previous estimates. Overall, we have high confidence 391 in our average estimates of V. cholerae positivity, despite the difficulty of accurately estimating 392 positivity in a new location/time/setting without confirmation tests.

393 These findings have several implications for cholera surveillance policy. The GTFCC 394 defines suspected cholera in areas where an outbreak has not yet been reported as acute

395 watery diarrhea and severe dehydration or death in individuals two years and older [17]. Our 396 finding that setting any minimum age increases specificity for identifying a true V. cholerae 397 infection in suspected cases supports using an age restriction in this case definition. The 398 February 2023 interim guidance from the GTFCC on cholera surveillance provides concrete 399 recommendations for systematic and frequent testing of suspected cholera cases at the health 400 facility or surveillance unit scale [17]. Our finding of high variability in positivity across settings 401 and times lends support to these recommendations of systematically generating local data that 402 can be used to scale suspected to true cholera. Our finding that high guality sampling also 403 increases specificity for V. cholerae suggests that systematically selecting cases to test is 404 important for accurately evaluating endemic cholera. Finally, that V. cholerae positivity was 405 lower during non-outbreak surveillance suggests that systematic confirmation testing is 406 additionally important for understanding cholera burden and epidemiology in endemic, non-407 outbreak settings where co-circulation of other enteric pathogens is common.

408 These estimates of V. cholerae positivity address one part of the challenge in 409 establishing the true burden of cholera: cases that are overcounted due to non-specific 410 suspected case definitions. A crucial next step will be to estimate missed cases due to care 411 seeking and poor clinical surveillance. This could be done in part through systematically 412 synthesizing data from studies of care seeking behavior for diarrheal symptoms (for example 413 [143,144]), including where potential cholera cases seek care (e.g., at pharmacies, traditional 414 healers, or hospitals). This could additionally be done through population representative surveys 415 and active case finding, similar to studies conducted in Haiti [145] and Tanzania [146], 416 respectively, which demonstrated higher mortality rates associated with cholera than had been 417 reported through passive surveillance. Together, these studies will help to understand whether 418 and to what degree missed cholera cases compensate for the biases described here in 419 overcounting.

| 420 | Ultimately, a better understanding of V. cholerae positivity will help us move towards |
|-------------------|--|
| 421 | estimates of true cholera incidence and mortality. Given the large heterogeneity between |
| 422 | studies, it will be important to do this in a way that accounts for variation in V. cholerae positivity |
| 423 | between sites. Moreover, the proportion of suspected cholera cases missed because of milder |
| 424 | symptoms or barriers to healthcare seeking needs to be estimated and accounted for. Such |
| 425 | estimates will provide crucial information to guide the allocation of limited resources such as |
| 426 | vaccines in a way that most effectively supports cholera prevention and control. |
| 427 | |
| 428 | Acknowledgments |
| 429 | We thank Morgane Dominguez for feedback on this manuscript, Lori Rosman for assistance |
| 430 | developing the literature search strategy, and Javier Perez-Saez for feedback on the analytical |
| 431 | methods. |
| 432 | |
| 433 | Funding |
| 434 | This work was supported by the Bill and Melinda Gates Foundation [grant number |
| 435 | OPP1171700] and the National Institute of Allergy and Infectious Disease [grant number |
| 436 | AI135115-01A1]. |
| 437 | |
| 438 | Conflicts of Interest |
| 439 | The authors declare no conflicts of interest. |
| 440 | |
| 441 | References |
| 442 443 444 | Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLOS Neglected Tropical Diseases. 2015;9: e0003832. doi:10.1371/journal.pntd.0003832 |

Lessler J, Moore SM, Luquero FJ, McKay HS, Grais R, Henkens M, et al. Mapping the
burden of cholera in sub-Saharan Africa and implications for control: an analysis of data

- 447 across geographical scales. The Lancet. 2018;391: 1908–1915. doi:10.1016/S0140-448 6736(17)33050-7
- Azman AS, Lauer SA, Bhuiyan TR, Luquero FJ, Leung DT, Hegde ST, et al. Vibrio
 cholerae O1 transmission in Bangladesh: insights from a nationally representative
 serosurvey. The Lancet Microbe. 2020;1: e336–e343. doi:10.1016/S2666-5247(20)301415
- 453 4. Mosley WH, Benenson AS, Barui R. A serological survey for cholera antibodies in rural
 454 East Pakistan. Bull World Health Organ. 1968;38: 327–334.
- 455 5. Weil AA, Begum Y, Chowdhury F, Khan AI, Leung DT, LaRocque RC, et al. Bacterial
 456 shedding in household contacts of cholera patients in Dhaka, Bangladesh. Am J Trop Med
 457 Hyg. 2014;91: 738–742. doi:10.4269/ajtmh.14-0095
- 458
 458
 459
 459
 459
 460
 460
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
 461
- 462 7. Camacho A, Bouhenia M, Alyusfi R, Alkohlani A, Naji MAM, Radiguès X de, et al. Cholera
 463 epidemic in Yemen, 2016–18: an analysis of surveillance data. The Lancet Global Health.
 464 2018;6: e680–e690. doi:10.1016/S2214-109X(18)30230-4
- Sauvageot D, Njanpop-Lafourcade B-M, Akilimali L, Anne J-C, Bidjada P, Bompangue D, et al. Cholera incidence and mortality in sub-Saharan African sites during multi-country surveillance. PLOS Neglected Tropical Diseases. 2016;10: e0004679. doi:10.1371/journal.pntd.0004679
- Jameel SK, Shafek MA, Abdulmohsen AM, Mohamed NS, Naji SR, Mohammed TT. The
 isolation of Vibrio cholera and other enteric bacteria with molecular characterization of
 Vibrio cholera during the outbreak of Baghdad/Iraq in 2015. Advances in Microbiology.
 2016;6: 699–715. doi:10.4236/aim.2016.69069
- Williams C, Cumming O, Grignard L, Rumedeka BB, Saidi JM, Grint D, et al. Prevalence
 and diversity of enteric pathogens among cholera treatment centre patients with acute
 diarrhea in Uvira, Democratic Republic of Congo. BMC Infectious Diseases. 2020;20: 741.
 doi:10.1186/s12879-020-05454-0
- Steenland MW, Joseph GA, Lucien MAB, Freeman N, Hast M, Nygren BL, et al.
 Laboratory-confirmed cholera and rotavirus among patients with acute diarrhea in four
 hospitals in Haiti, 2012–2013. Am J Trop Med Hyg. 2013;89: 641–646.
 doi:10.4269/ajtmh.13-0307
- Siddique AK, Ahmed S, Iqbal A, Sobhan A, Poddar G, Azim T, et al. Epidemiology of
 rotavirus and cholera in children aged less than five years in rural Bangladesh. J Health
 Popul Nutr. 2011;29: 1–8. doi:10.3329/jhpn.v29i1.7560
- 13. Nadri J, Sauvageot D, Njanpop-Lafourcade B-M, Baltazar CS, Banla Kere A, Bwire G, et
 al. Sensitivity, specificity, and public-health utility of clinical case definitions based on the

- 486 signs and symptoms of cholera in Africa. The American Journal of Tropical Medicine and
 487 Hygiene. 2018;98: 1021–1030. doi:10.4269/ajtmh.16-0523
- Lucien MAB, Schaad N, Steenland MW, Mintz ED, Emmanuel R, Freeman N, et al.
 Identifying the most sensitive and specific sign and symptom combinations for cholera:
 results from an analysis of laboratory-based surveillance data from Haiti, 2012–2013. The
 American Journal of Tropical Medicine and Hygiene. 2015;92: 758–764.
 doi:10.4269/ajtmh.14-0429
- 493 15. Muzembo BA, Kitahara K, Debnath A, Okamoto K, Miyoshi S-I. Accuracy of cholera rapid
 494 diagnostic tests: a systematic review and meta-analysis. Clinical Microbiology and
 495 Infection. 2021;0. doi:10.1016/j.cmi.2021.08.027
- 496 16. Ontweka LN, Deng LO, Rauzier J, Debes AK, Tadesse F, Parker LA, et al. Cholera rapid
 497 test with enrichment step has diagnostic performance equivalent to culture. PLOS ONE.
 498 2016;11: e0168257. doi:10.1371/journal.pone.0168257
- 499 17. Global Task Force on Cholera Control (GTFCC) Surveillance Working Group. Public health
 500 surveillance for cholera interim guidance. 2023. Available: https://www.gtfcc.org/wp 501 content/uploads/2023/02/gtfcc-public-health-surveillance-for-cholera-interim-guidance.pdf
- 502 18. Global Task Force on Cholera Control. Identification of priority areas for multisectoral 503 interventions (PAMIs) for cholera control. [cited 16 May 2023]. Available:
 504 https://www.gtfcc.org/resources/identification-of-priority-areas-for-multisectoral-505 interventions-pamis-for-cholera-control/
- Weill F-X, Domman D, Njamkepo E, Tarr C, Rauzier J, Fawal N, et al. Genomic history of
 the seventh pandemic of cholera in Africa. Science. 2017;358: 785–789.
 doi:10.1126/science.aad5901
- 509 20. HERVE M. RVAideMemoire: testing and plotting procedures for biostatistics. 2023.
 510 Available: https://cran.r-project.org/web/packages/RVAideMemoire/index.html
- 511 21. Wickham H, Chang W, Henry L, Pedersen TL, Takahashi K, Wilke C, et al. ggplot2: create
 512 elegant data visualisations using the grammar of graphics. 2023. Available: https://cran.r 513 project.org/web/packages/ggplot2/index.html
- 514 22. Wang C, Lin X, Nelson KP. Bayesian hierarchical latent class models for estimating diagnostic accuracy. Stat Methods Med Res. 2020;29: 1112–1128.
 516 doi:10.1177/0962280219852649
- 517 23. Plummer M, Stukalov A, Denwood M. rjags: Bayesian graphical models using MCMC.
 518 2022. Available: https://CRAN.R-project.org/package=rjags
- S19 24. R Core Team. R: A language and environment for statistical computing. R Foundation for
 Statistical Computing, Vienna, Austria. http://wwwR-project.org/. 2016 [cited 17 Aug 2022].
 Available: https://cir.nii.ac.jp/crid/1574231874043578752
- 522 25. Debes AK, Murt KN, Waswa E, Githinji G, Umuro M, Mbogori C, et al. Laboratory and field
 523 evaluation of the Crystal VC-O1 cholera rapid diagnostic test. The American Journal of
 524 Tropical Medicine and Hygiene. 2021;104: 2017–2023. doi:10.4269/ajtmh.20-1280

- 525 26. Mwaba J, Ferreras E, Chizema-Kawesa E, Mwimbe D, Tafirenyika F, Rauzier J, et al.
 526 Evaluation of the SD bioline cholera rapid diagnostic test during the 2016 cholera outbreak
 527 in Lusaka, Zambia. Tropical Medicine & International Health. 2018;23: 834–840.
 528 doi:10.1111/tmi.13084
- 529 27. Sayeed MA, Islam K, Hossain M, Akter NJ, Alam MN, Sultana N, et al. Development of a new dipstick (Cholkit) for rapid detection of Vibrio cholerae O1 in acute watery diarrheal stools. PLOS Neglected Tropical Diseases. 2018;12: e0006286.
 532 doi:10.1371/journal.pntd.0006286
- 533 28. Gabry J, Češnovar R, Bales B, Morris M, Popov M, Lawrence M, et al. R interface to 534 CmdStan. 2022 [cited 17 Aug 2022]. Available: https://mc-stan.org/cmdstanr/
- 535 29. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med.
 536 2002;21: 1539–1558. doi:10.1002/sim.1186
- 537 30. Viechtbauer W. I2 for multilevel and multivariate models. 2022 [cited 26 Aug 2022].
 538 Available: https://www.metafor-project.org/doku.php/tips:i2_multilevel_multivariate
- 31. Abdullahi KN, Mutindin D, Kabugi W, Mowlid S. Epidemiological description of a protracted cholera outbreak in Hagadera refugee camp and the surrounding host community within
 541 Fafi Sub County and Garissa County in Kenya during march-September 2019. Epidemiol Open J. 2019;4: 31–5.
- Ahmed S, Afzal RK, Mian UA. A localized outbreak of cholera due to Vibrio cholerae 01,
 Ogawa resistant to tetracyclines. PAFMJ. 2015;65: 595–599.
- 33. Alajo SO, Nakavuma J, Erume J. Cholera in endemic districts in Uganda during El Niño
 rains: 2002-2003. Afr Health Sci. 2006;6: 93–7. doi:10.5555/afhs.2006.6.2.93
- Alkassoum S, Djibo I, Amadou H, Bohari A, Issoufou H, Aka J, et al. The global burden of
 cholera outbreaks in Niger: an analysis of the national surveillance data, 2003–2015.
 Transactions of the Royal Society of Tropical Medicine and Hygiene. 2019;113: 273–280.
- 35. Amadu DO, Abdullahi IN, Seibu E, Fadeyi A, Kamaldeen K, Akanbi AA, et al.
 Retrospective analysis of the serovars and antibiogram of Vibrio cholerae isolates of the
 2017 Ilorin Cholera Outbreak, Nigeria. Infect Chemother. 2021;53: 368–373.
 doi:10.3947/ic.2021.0001
- 36. Anh DD, Lopez AL, Thiem VD, Grahek SL, Duong TN, Park JK, et al. Use of oral cholera
 vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis. 2011;5:
 e1006. doi:10.1371/journal.pntd.0001006
- 37. Baltazar CS, Langa JP, Baloi LD, Wood R, Ouedraogo I, Njanpop-Lafourcade B-M, et al.
 Multi-site cholera surveillance within the African Cholera Surveillance Network shows
 endemicity in Mozambique, 2011–2015. PLOS Neglected Tropical Diseases. 2017;11:
 e0005941. doi:10.1371/journal.pntd.0005941
- 38. Bhattacharya MK, Dutta D, Ramamurthy T, Sarkar D, Singharoy A, Bhattacharya SK.
 Azithromycin in the treatment of cholera in children. Acta Paediatr. 2003;92: 676–8.

- 39. Bhuiyan NA, Qadri F, Faruque ASG, Malek MA, Salam MA, Nato F, et al. Use of dipsticks
 for rapid diagnosis of cholera caused by Vibrio cholerae O1 and O139 from rectal swabs. J
 Clin Microbiol. 2003;41: 3939–3941. doi:10.1128/JCM.41.8.3939-3941.2003
- 566 40. Bin-Hameed EA, Joban HA. Cholera outbreak in Hadhramout, Yemen: the epidemiological
 567 weeks 2019. International Journal of Epidemiologic Research. 2021;8: 40–46.
- 568 41. Brazilay E, Schaad N, Magloire R. Cholera surveillance during the Haiti epidemic-the first
 569 two years. N Engl J Med. 2013;368: 599–609.
- 42. Bukar AM, Goni HB, Bwala AB, Kolo FB, Isa A, Ibrahim A, et al. Determination of cholera
 outbreak among internally displaced persons (IDPs) in complex emergency settings within
 Maiduguri, Borno State-Nigeria.
- 43. Bwire G, Malimbo M, Maskery B, Kim YE, Mogasale V, Levin A. The burden of cholera in Uganda. PLoS Negl Trop Dis. 2013;7: e2545. doi:10.1371/journal.pntd.0002545
- 575 44. Bwire G, Waniaye JB, Otim JS, Matseketse D, Kagirita A, Orach CG. Cholera risk in cities
 576 in Uganda: understanding cases and contacts centered strategy (3CS) for rapid cholera
 577 outbreak control. Pan Afr Med J. 2021;39: 193. doi:10.11604/pamj.2021.39.193.27794
- 45. Chibwe I, Kasambara W, Kagoli M, Milala H, Gondwe C, Azman AS. Field evaluation of
 579 Cholkit rapid diagnostic test for Vibrio cholerae O1 during a cholera outbreak in Malawi,
 580 2018. Open Forum Infectious Diseases. 2020;7. doi:10.1093/ofid/ofaa493
- 581 46. Chirambo R, Mufunda J, Songolo P, Kachimba J, Vwalika B. Epidemiology of the 2016
 582 cholera outbreak of Chibombo district, central Zambia. Medical Journal of Zambia.
 583 2016;43: 61–63.
- 584 47. Chowdhury G, Senapati T, Das B, Kamath A, Pal D, Bose P, et al. Laboratory evaluation of
 585 the rapid diagnostic tests for the detection of Vibrio cholerae O1 using diarrheal samples.
 586 PLOS Neglected Tropical Diseases. 2021;15: e0009521.
 587 doi:10.1371/journal.pntd.0009521
- 48. Das S, Gupta S. Diversity of Vibrio cholerae strains isolated in Delhi, India, during 19922000. J Health Popul Nutr. 2005;23: 44–51.
- 49. De Guzman A, de los Reyes VC, Sucaldito MN, Tayag E. Availability of safe drinkingwater: the answer to cholera outbreak? Nabua, Camarines Sur, Philippines, 2012. Western
 Pac Surveill Response J. 2015;6: 12–6. doi:10.5365/wpsar.2015.6.1.005
- 593 50. Debes AK, Ateudjieu J, Guenou E, Ebile W, Sonkoua IT, Njimbia AC, et al. Clinical and
 594 environmental surveillance for Vibrio cholerae in resource constrained areas: application
 595 during a 1-year surveillance in the Far North Region of Cameroon. Am J Trop Med Hyg.
 596 2016;94: 537–543. doi:10.4269/ajtmh.15-0496
- 597 51. Dengo-Baloi LC, Semá-Baltazar CA, Manhique LV, Chitio JE, Inguane DL, Langa JP.
 598 Antibiotics resistance in El Tor Vibrio cholerae 01 isolated during cholera outbreaks in
 599 Mozambique from 2012 to 2015. PLOS ONE. 2017;12: e0181496.
 600 doi:10.1371/journal.pone.0181496

- 52. Djomassi L, Gessner B, Andze G, Mballa G. Cholera epidemiology in Cameroon based on national surveillance data. J Infect Dis. 2013;208: S92–S97.
- 53. Dutta BP, Kumar N, Meshram KC, Yadav R, Sodha SV, Gupta S. Cholera outbreak
 associated with contaminated water sources in paddy fields, Mandla District, Madhya
 Pradesh, India. Indian J Public Health. 2021;65: S46-s50. doi:10.4103/ijph.IJPH_1118_20
- 54. Dzotsi EK, Dongdem AZ, Boateng G, Antwi L, Owusu-Okyere G, Nartey DB, et al.
 Surveillance of bacterial pathogens of diarrhoea in two selected sub metros within the
 Accra metropolis. Ghana Med J. 2015;49: 65–71. doi:10.4314/gmj.v49i2.1
- 55. Eurien D, Mirembe BB, Musewa A, Kisaakye E, Kwesiga B, Ogole F, et al. Cholera
 Outbreak Caused by Drinking Unprotected Well Water Contaminated with Feces from an
 Open Storm Water Drainage—Kampala City, Uganda, January 2019. 2020.
- 56. Fouda AAB, Kollo B. Epidémie de choléra à Douala en 2011 épidémiologie, clinique et
 bactériologie Cholera outbreak in Douala in 2011 epidemiology, clinic and bacteriology.
- 57. Franke MF, Jerome JG, Matias WR, Ternier R, Hilaire IJ, Harris JB, et al. Comparison of
 two control groups for estimation of oral cholera vaccine effectiveness using a case-control
 study design. Vaccine. 2017;35: 5819–5827. doi:10.1016/j.vaccine.2017.09.025
- 58. Fredrick T, Ponnaiah M, Murhekar MV, Jayaraman Y, David JK, Vadivoo S, et al. Cholera
 outbreak linked with lack of safe water supply following a tropical cyclone in Pondicherry,
 India, 2012. J Health Popul Nutr. 2015;33: 31–8.
- 620 59. George CM, Rashid MU, Sack DA, Bradley Sack R, Saif-Ur-Rahman KM, Azman AS, et al.
 621 Evaluation of enrichment method for the detection of Vibrio cholerae O1 using a rapid
 622 dipstick test in Bangladesh. Trop Med Int Health. 2014;19: 301–307.
 623 doi:10.1111/tmi.12252
- 624 60. Grandesso F, Kasambara W, Page AL, Debes AK, M'Bang'ombe M, Palomares A, et al.
 625 Effectiveness of oral cholera vaccine in preventing cholera among fishermen in Lake
 626 Chilwa, Malawi: a case-control study. Vaccine. 2019;37: 3668–3676.
 627 doi:10.1016/j.vaccine.2019.05.044
- 61. Guévart E, Noeske J, Sollé J, Mouangue A, Bikoti JM. Large-scale selective antibiotic
 prophylaxis during the 2004 cholera outbreak in Douala (Cameroon). Sante. 2007;17: 63–
 8.
- 631 62. Gupta PK, Pant ND, Bhandari R, Shrestha P. Cholera outbreak caused by drug resistant
 632 Vibrio cholerae serogroup O1 biotype EITor serotype Ogawa in Nepal; a cross-sectional
 633 study. Antimicrob Resist Infect Control. 2016;5: 23. doi:10.1186/s13756-016-0122-7
- 634 63. Gupta S, Jhamb U, Uppal B, Chakraverti A, Mittal SK. Diagnosing cholera in the young: a 635 review of W.H.O. criteria. JK Science. 2007;9: 137–139.
- 636 64. Haque F. Cholera outbreak in Netrokona Municipality, 2013. Health Science Bulletin.
 637 2014;12.

- 638 65. Haque F, Hossain MJ, Kundu SK, Naser AM, Rahman M, Luby SP. Cholera outbreaks in
 639 Urban Bangladesh in 2011. Epidemiology (Sunnyvale). 2013;3. doi:10.4172/2161640 1165.1000126
- 64. Harris JR, Cavallaro EC, De Nóbrega AA, Dos S. Barrado JC, Bopp C, Parsons MB, et al.
 Field evaluation of Crystal VC® Rapid Dipstick test for cholera during a cholera outbreak in
 Guinea-Bissau. Tropical Medicine & International Health. 2009;14: 1117–1121.
- 644 67. Im J, Islam MT, Ahmmed F, Kim DR, Chon Y, Zaman K, et al. Use of oral cholera vaccine
 645 as a vaccine probe to determine the burden of culture-negative cholera. PLOS Neglected
 646 Tropical Diseases. 2019;13: e0007179. doi:10.1371/journal.pntd.0007179
- 647 68. Ingelbeen B, Hendrickx D, Miwanda B, van der Sande MAB, Mossoko M, Vochten H, et al.
 648 Recurrent cholera outbreaks, Democratic Republic of the Congo, 2008-2017. Emerg Infect
 649 Dis. 2019;25: 856–864. doi:10.3201/eid2505.181141
- 650 69. Islam MT, Khan AI, Sayeed MA, Amin J, Islam K, Alam N, et al. Field evaluation of a
 651 locally produced rapid diagnostic test for early detection of cholera in Bangladesh. PLOS
 652 Neglected Tropical Diseases. 2019;13: e0007124. doi:10.1371/journal.pntd.0007124
- 653 70. Issahaku GR, Asiedu-Bekoe F, Kwashie S, Broni F, Boateng P, Alomatu H, et al.
 654 Protracted cholera outbreak in the Central Region, Ghana, 2016. Ghana Med J. 2020;54:
 655 45–52. doi:10.4314/gmj.v54i2s.8
- Jain A, Choudhary S, Saroha E, Bhatnagar P, Harvey P. Cholera outbreak in an informal
 settlement at Shahpur huts, Panchkula District, Haryana State, India, 2019. Indian J Public
 Health. 2021;65: S51-s54. doi:10.4103/ijph.IJPH_970_20
- Jeandron A, Cumming O, Rumedeka BB, Saidi JM, Cousens S. Confirmation of cholera by
 rapid diagnostic test amongst patients admitted to the cholera treatment centre in Uvira,
 Democratic Republic of the Congo. PLOS ONE. 2018;13: e0201306.
 doi:10.1371/journal.pone.0201306
- Jones FK, Wamala JF, Rumunu J, Mawien PN, Kol MT, Wohl S, et al. Successive
 epidemic waves of cholera in South Sudan between 2014 and 2017: a descriptive
 epidemiological study. The Lancet Planetary Health. 2020;4: e577–e587.
 doi:10.1016/S2542-5196(20)30255-2
- Khatib A, Ali M, von Seidlein L, Kim D, Hashim R, Reyburn R. Direct and indirect
 effectiveness of an oral cholera vaccine in Zanzibar, East Africa: findings from a large
 mass vaccination campaign followed by an observational cohort study. Lancet Infect Dis.
 2012;12: 837–44.
- 671 75. Khazaei HA, Rezaei N, Bagheri GR, Moin AA. A six-year study on Vibrio cholerae in southeastern Iran. Jpn J Infect Dis. 2005;58: 8–10.

Kisera N, Luxemburger C, Tornieporth N, Otieno G, Inda J. A descriptive cross-sectional
study of cholera at Kakuma and Kalobeyei refugee camps, Kenya in 2018. Pan Afr Med J.
2020;37: 197. doi:10.11604/pamj.2020.37.197.24798

- Koley H, Ray N, Chowdhury G, Barman S, Mitra S, Ramamurthy T, et al. Outbreak of
 cholera caused by Vibrio cholerae O1 El Tor variant strain in Bihar, India. Jpn J Infect Dis.
 2014;67: 221–6. doi:10.7883/yoken.67.221
- Kulkarni S, Chillarge C. Antibiotic susceptibility pattern of Vibrio cholerae causing
 diarrohea outbreaks in Bidar, North Karnataka, India. Int J Curr Microbiol App Sci. 2015;4:
 957–961.
- Kuttiat VS, Lodha R, Das B, Kohli U. Prevalence of cholera in pediatric patients with acute
 dehydrating diarrhea. Indian J Pediatr. 2010;77: 67–71. doi:10.1007/s12098-010-0009-1
- 80. Kwesiga B, Pande G, Ario AR, Tumwesigye NM, Matovu JK, Zhu B-P. A prolonged,
 community-wide cholera outbreak associated with drinking water contaminated by sewage
 in Kasese District, western Uganda. BMC Public Health. 2018;18: 1–8.
- 81. Landoh DE, Gessner BD, Badziklou K, Tamekloe T, Nassoury DI, Dagnra A, et al. National
 surveillance data on the epidemiology of cholera in Togo. J Infect Dis. 2013;208 Suppl 1:
 S115-9. doi:10.1093/infdis/jit244
- 82. Lenglet A, Khamphaphongphane B, Thebvongsa P, Vongprachanh P, Sithivong N,
 691 Chantavisouk C, et al. A cholera epidemic in Sekong Province, Lao People's Democratic
 692 Republic, December 2007-January 2008. Jpn J Infect Dis. 2010;63: 204–7.
- 83. Ley B, Khatib AM, Thriemer K, von Seidlein L, Deen J, Mukhopadyay A, et al. Evaluation
 of a rapid dipstick (Crystal VC) for the diagnosis of cholera in Zanzibar and a comparison
 with previous studies. PLoS One. 2012;7: e36930. doi:10.1371/journal.pone.0036930
- 84. Llanes R, Lazo A, Somarriba L, Mas P. Sentinel surveillance detects low circulation of
 Vibrio cholerae serotype Inaba in Haiti, 2011-2012. MEDICC Rev. 2015;17: 43–6.
 doi:10.37757/mr2015.V17.N3.9
- 85. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. Use of Vibrio
 cholerae vaccine in an outbreak in Guinea. N Engl J Med. 2014;370: 2111–20.
 doi:10.1056/NEJMoa1312680
- 86. Mahamud AS, Ahmed JA, Nyoka R, Auko E, Kahi V, Ndirangu J, et al. Epidemic cholera in
 Kakuma Refugee Camp, Kenya, 2009: the importance of sanitation and soap. J Infect Dev
 Ctries. 2012;6: 234–41. doi:10.3855/jidc.1966
- 87. Matias WR, Cademil A, Julceus FE, Mayo-Smith LM, Franke MF, Harris JB, et al.
 Laboratory evaluation of immunochromatographic rapid diagnostic tests for cholera in
 Haiti. American Journal of Tropical Medicine and Hygiene. 2015;93: 569–569.
- 88. Mbala-Kingebeni P, Vogt F, Miwanda B, Sundika T, Mbula N, Pankwa I, et al. Sachet
 water consumption as a risk factor for cholera in urban settings: findings and implications
 from a case control study in Kinshasa, Democratic Republic of the Congo during the 20172018 outbreak. 2020.
- 89. Michel E, Gaudart J, Beaulieu S, Bulit G, Piarroux M, Boncy J, et al. Estimating
 effectiveness of case-area targeted response interventions against cholera in Haiti. Elife.
 2019;8. doi:10.7554/eLife.50243

- 90. Mishra A, Taneja N, Sharma M. Environmental and epidemiological surveillance of Vibrio
 cholerae in a cholera-endemic region in India with freshwater environs. Journal of Applied
 Microbiology. 2012;112: 225–237.
- Monje F, Ario AR, Musewa A, Bainomugisha K, Mirembe BB, Aliddeki DM, et al. A
 prolonged cholera outbreak caused by drinking contaminated stream water, Kyangwali
 refugee settlement, Hoima District, Western Uganda: 2018. Infect Dis Poverty. 2020;9:
 154. doi:10.1186/s40249-020-00761-9
- Mugoya I, Kariuki S, Galgalo T, Njuguna C, Omollo J, Njoroge J, et al. Rapid spread of
 Vibrio cholerae O1 throughout Kenya, 2005. Am J Trop Med Hyg. 2008;78: 527–33.
- Mukherjee P, Ghosh S, Ramamurthy T, Bhattacharya MK, Nandy RK, Takeda Y, et al.
 Evaluation of a rapid immunochromatographic dipstick kit for diagnosis of cholera emphasizes its outbreak utility. Jpn J Infect Dis. 2010;63: 234–8.
- Mwenda V, Niyomwungere A, Oyugi E, Githuku J, Obonyo M, Gura Z. Factors associated
 with cholera outbreaks, Nairobi County, July 2017: a case control study. bioRxiv. 2019;
 719641.
- 95. Ndugwa Kabwama S, Riolexus Ario A, Guwatudde D. Cholera outbreak caused by drinking
 r31 lakeshore water contaminated by feces washed down from a hill-side residential area:
 r32 Kaiso Village, Uganda. Pan Afr med J-Conference Proceedings. 2017.
- 96. Noora CL, Issah K, Kenu E, Bachan EG, Nuoh RD, Nyarko KM, et al. Large cholera
 outbreak in Brong Ahafo Region, Ghana. BMC Res Notes. 2017;10: 389.
 doi:10.1186/s13104-017-2728-0
- 736 97. Nsubuga F, Garang SC, Tut M, Oguttu D, Lubajo R, Lodiongo D, et al. Epidemiological
 737 description of a protracted cholera outbreak in Tonj East and Tonj North counties, former
 738 Warrap State, South Sudan, May-Oct 2017. BMC Infect Dis. 2019;19: 4.
 739 doi:10.1186/s12879-018-3640-5
- 98. Okello PE, Bulage L, Riolexus AA, Kadobera D, Kwesiga B, Kajumbula H, et al. A cholera
 outbreak caused by drinking contaminated river water, Bulambuli District, Eastern Uganda,
 March 2016. BMC Infect Dis. 2019;19: 516. doi:10.1186/s12879-019-4036-x
- Page AL, Alberti KP, Mondonge V, Rauzier J, Quilici ML, Guerin PJ. Evaluation of a rapid
 test for the diagnosis of cholera in the absence of a gold standard. PLoS One. 2012;7:
 e37360. doi:10.1371/journal.pone.0037360
- 746 100. Pal BB, Khuntia HK, Samal SK, Kerketta AS, Kar SK, Karmakar M, et al. Large outbreak of
 747 cholera caused by El Tor variant Vibrio cholerae O1 in the eastern coast of Odisha, India
 748 during 2009. Epidemiol Infect. 2013;141: 2560–7. doi:10.1017/s0950268813000368
- 749 101. Pal BB, Khuntia HK, Samal SK, Das SS, Chhotray GP. Emergence of Vibrio cholerae O1
 750 biotype E1 Tor serotype Inaba causing outbreaks of cholera in Orissa, India. Japanese
 751 Journal of Infectious Diseases. 2006;59: 266.
- Pande G, Kwesiga B, Bwire G, Kalyebi P, Riolexus A, Matovu JKB, et al. Cholera outbreak
 caused by drinking contaminated water from a lakeshore water-collection site, Kasese

- District, south-western Uganda, June-July 2015. PLoS One. 2018;13: e0198431.
 doi:10.1371/journal.pone.0198431
- 756 103. Phukan AC, Borah PK, Biswas D, Mahanta J. A cholera epidemic in a rural area of
 757 northeast India. Trans R Soc Trop Med Hyg. 2004;98: 563–6.
 758 doi:10.1016/j.trstmh.2004.01.002
- 104. Ramazanzadeh R, Rouhi S, Shakib P, Shahbazi B, Bidarpour F, Karimi M. Molecular
 characterization of Vibrio cholerae isolated from clinical samples in Kurdistan Province,
 Iran. Jundishapur J Microbiol. 2015;8: e18119. doi:10.5812/jjm.8(5)2015.18119
- 105. Rosewell A, Addy B, Komnapi L, Makanda F, Ropa B, Posanai E, et al. Cholera risk
 factors, Papua New Guinea, 2010. BMC Infect Dis. 2012;12: 287. doi:10.1186/1471-233412-287
- 106. Roskosky M, Acharya B, Shakya G, Karki K, Sekine K, Bajracharya D, et al. Feasibility of a
 comprehensive targeted cholera intervention in the Kathmandu Valley, Nepal. Am J Trop
 Med Hyg. 2019;100: 1088–1097. doi:10.4269/ajtmh.18-0863
- 107. Roy S, Parande MV, Mantur BG, Bhat S, Shinde R, Parande AM, et al. Multidrug-resistant
 Vibrio cholerae O1 in Belgaum, south India. J Med Microbiol. 2012;61: 1574–1579.
 doi:10.1099/jmm.0.049692-0
- 108. Sack RB, Siddique AK, Longini IM Jr, Nizam A, Yunus M, Islam MS, et al. A 4-year study
 of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh. J Infect Dis.
 2003;187: 96–101. doi:10.1086/345865
- 109. Saha R, Das S, Waghmare M, Ramachandran VG. Paradoxical reduction in prevalence of
 vibrio cholerae in its niche environment. International Journal of Pharma and Bio Sciences.
 2013;4: B1099–B1107.
- 110. Sévère K, Rouzier V, Anglade SB, Bertil C, Joseph P, Deroncelay A, et al. Effectiveness of
 oral cholera vaccine in Haiti: 37-month follow-up. Am J Trop Med Hyg. 2016;94: 1136–42.
 doi:10.4269/ajtmh.15-0700
- 111. Shah WA, Shahina M, Ali N. First report of Vibrio cholerae infection from Andaman and
 Nicobar, India. J Commun Dis. 2002;34: 270–5.
- 112. Sharma A, Dutta BS, Rasul ES, Barkataki D, Saikia A, Hazarika NK. Prevalence of Vibrio
 cholerae O1 serogroup in Assam, India: A hospital-based study. Indian J Med Res.
 2017;146: 401–408. doi:10.4103/ijmr.IJMR_631_15
- 113. Shikanga OT, Mutonga D, Abade M, Amwayi S, Ope M, Limo H, et al. High mortality in a
 cholera outbreak in western Kenya after post-election violence in 2008. Am J Trop Med
 Hyg. 2009;81: 1085–90. doi:10.4269/ajtmh.2009.09-0400
- 114. Siddiqui FJ, Bhutto NS, von Seidlein L, Khurram I, Rasool S, Ali M, et al. Consecutive
 outbreaks of Vibrio cholerae O139 and V. cholerae O1 cholera in a fishing village near
 Karachi, Pakistan. Trans R Soc Trop Med Hyg. 2006;100: 476–82.
 doi:10.1016/j.trstmh.2005.07.019
- 27

- 115. Sinha A, Sengupta S, Ghosh S, Basu S, Sur D, Kanungo S, et al. Evaluation of a rapid
 dipstick test for identifying cholera cases during the outbreak. Indian J Med Res. 2012;135:
 523–8.
- T16. Sreedhara H, Mohan N. Molecular epidemiology of vibrio cholerae causing outbreaks and
 sporadic cholera in and around Hassan district and its antibiotic susceptibility pattern. IP Int
 J Med Microbiol Trop Dis. 2019;5: 41–46.
- 117. Sugunan AP, Ghosh AR, Roy S, Gupte MD, Sehgal SC. A cholera epidemic among the
 Nicobarese tribe of Nancowry, Andaman, and Nicobar, India. Am J Trop Med Hyg.
 2004;71: 822–7.
- 118. Sur D, Deen JL, Manna B, Niyogi SK, Deb AK, Kanungo S, et al. The burden of cholera in
 the slums of Kolkata, India: data from a prospective, community based study. Arch Dis
 Child. 2005;90: 1175–81. doi:10.1136/adc.2004.071316
- 804 119. Sur D, Sarkar BL, Manna B, Deen J, Datta S, Niyogi SK, et al. Epidemiological,
 805 microbiological & electron microscopic study of a cholera outbreak in a Kolkata slum
 806 community. Indian J Med Res. 2006;123: 31–6.
- 120. Tamang M, Sharma N, Makaju R, Sarma A, Koju R, Nepali N, et al. An outbreak of El Tor
 cholera in Kavre district. Nepal KUMJ. 2005;3: 138–142.
- 121. Taneja N, Kaur J, Sharma K, Singh M, Kalra JK, Sharma NM, et al. A recent outbreak of
 cholera due to Vibrio cholerae O1 Ogawa in & around Chandigarh, North India. Indian J
 Med Res. 2003;117: 243–6.
- 122. Thiem VD, Deen JL, von Seidlein L, Canh DG, Anh DD, Park JK, et al. Long-term
 effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam.
 Vaccine. 2006;24: 4297–303. doi:10.1016/j.vaccine.2006.03.008
- 815 123. Torane V, Kuyare S, Nataraj G, Mehta P, Dutta S, Sarkar B. Phenotypic and antibiogram
 816 pattern of V. cholerae isolates from a tertiary care hospital in Mumbai during 2004-2013: a
 817 retrospective cross-sectional study. BMJ Open. 2016;6: e012638. doi:10.1136/bmjopen818 2016-012638
- 124. Tripurari K, Deepak B, Kaur TA, Pushpa VV, Aakash S, Prakash NJ, et al. Vibrio cholerae
 outbreak in Batala town, Punjab, India 2012. Journal of Communicable Diseases. 2017;49:
 35–40. doi:10.24321/0019.5138.201705
- 125. Uthappa CK, Allam RR, Nalini C, Gunti D, Udaragudi PR, Tadi GP, et al. An outbreak of
 cholera in Medipally village, Andhra Pradesh, India, 2013. J Health Popul Nutr. 2015;33: 7.
 doi:10.1186/s41043-015-0021-1
- 825 126. Von Nguyen D, Sreenivasan N, Lam E, Ayers T, Kargbo D, Dafae F, et al. Cholera
 826 epidemic associated with consumption of unsafe drinking water and street-vended water827 Eastern Freetown, Sierra Leone, 2012. American Journal of Tropical Medicine and
 828 Hygiene. 2014;90: 518–523. doi:10.4269/ajtmh.13-0567

- 127. Wang XY, Ansaruzzaman M, Vaz R, Mondlane C, Lucas ME, von Seidlein L, et al. Field
 evaluation of a rapid immunochromatographic dipstick test for the diagnosis of cholera in a
 high-risk population. BMC Infect Dis. 2006;6: 17. doi:10.1186/1471-2334-6-17
- 832 128. Wierzba TF, Kar SK, Mogasale VV, Kerketta AS, You YA, Baral P, et al. Effectiveness of
 833 an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State,
 834 India. Vaccine. 2015;33: 2463–2469. doi:10.1016/j.vaccine.2015.03.073
- 835 129. Zachariah R, Harries AD, Arendt V, Nchingula D, Chimtulo F, Courteille O, et al.
 836 Characteristics of a cholera outbreak, patterns of Vibrio cholerae and antibiotic
 837 susceptibility testing in rural Malawi. Trans R Soc Trop Med Hyg. 2002;96: 39–40.
 838 doi:10.1016/s0035-9203(02)90233-6
- 130. Zereen F, Akter S, Sobur MA, Hossain MT, Rahman MT. Molecular detection of Vibrio
 cholerae from human stool collected from SK Hospital, Mymensingh, and their
 antibiogram. J Adv Vet Anim Res. 2019;6: 451–455. doi:10.5455/javar.2019.f367
- 131. Zgheir SM, Mustafa NM, Ali AA, Al-Diwan J. Cholera outbreak in Iraq, 2017. Ind Jour of
 Publ Health Rese & Develop. 2019;10: 686. doi:10.5958/0976-5506.2019.01654.1
- 132. Azman AS, Parker LA, Rumunu J, Tadesse F, Grandesso F, Deng LL, et al. Effectiveness
 of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. The
 Lancet Global Health. 2016;4: e856–e863. doi:10.1016/S2214-109X(16)30211-X
- 847 133. Blake A, Keita VS, Sauvageot D, Saliou M, Njanpop BM, Sory F, et al. Temporo-spatial
 848 dynamics and behavioural patterns of 2012 cholera epidemic in the African mega-city of
 849 Conakry, Guinea. Infectious Diseases of Poverty. 2018;7: 13. doi:10.1186/s40249-018850 0393-8
- 134. Boncy J, Rossignol E, Dahourou G, Hast M, Buteau J, Stanislas M, et al. Performance and utility of a rapid diagnostic test for cholera: notes from Haiti. Diagnostic Microbiology and Infectious Disease. 2013;76: 521–523. doi:10.1016/j.diagmicrobio.2013.03.010
- 135. Bwire G, Orach CG, Abdallah D, Debes AK, Kagirita A, Ram M, et al. Alkaline peptone
 water enrichment with a dipstick test to quickly detect and monitor cholera outbreaks. BMC
 Infectious Diseases. 2017;17: 726. doi:10.1186/s12879-017-2824-8
- 136. Ferreras E, Blake A, Chewe O, Mwaba J, Zulu G, Poncin M, et al. Alternative observational
 designs to estimate the effectiveness of one dose of oral cholera vaccine in Lusaka,
 Zambia. Epidemiol Infect. 2020;148: e78. doi:10.1017/S095026882000062X
- 137. Franke MF, Ternier R, Jerome JG, Matias WR, Harris JB, Ivers LC. Long-term
 effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in
 Haiti: an extended case-control study. The Lancet Global Health. 2018;6: e1028–e1035.
 doi:10.1016/S2214-109X(18)30284-5
- 138. George CM, Monira S, Sack DA, Rashid M, Saif-Ur-Rahman KM, Mahmud T, et al.
 Randomized controlled trial of hospital-Bbased hygiene and water treatment intervention (CHoBI7) to reduce cholera. Emerg Infect Dis. 2016;22: 233–241.
 doi:10.3201/eid2202.151175

- 139. Ivers LC, Hilaire IJ, Teng JE, Almazor CP, Jerome JG, Ternier R, et al. Effectiveness of
 reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator
 analysis. The Lancet Global Health. 2015;3: e162–e168. doi:10.1016/S2214109X(14)70368-7
- 140. Lucas MES, Deen JL, von Seidlein L, Wang X-Y, Ampuero J, Puri M, et al. Effectiveness of
 mass oral cholera vaccination in Beira, Mozambique. New England Journal of Medicine.
 2005;352: 757–767. doi:10.1056/NEJMoa043323
- 141. Roy S, Dutta B, Ghosh AR, Sugunan AP, Nandy RK, Bhattacharya SK, et al. Molecular
 tracking of the lineage of strains of Vibrio cholerae O1 biotype El Tor associated with a
 cholera outbreak in Andaman and Nicobar Islands, India. Trop Med Int Health. 2005;10:
 604–611. doi:10.1111/j.1365-3156.2005.01423.x
- 879 142. Guillaume Y, Debela M, Slater D, Vissieres K, Ternier R, Franke M, et al. Poor sensitivity
 880 of stool culture compared to PCR in surveillance for V. cholerae in Haiti, 2018-2019. Open
 881 Forum Infectious Diseases. 2023; ofad301. doi:10.1093/ofid/ofad301
- 143. Chowdhury F, Khan IA, Patel S, Siddiq AU, Saha NC, Khan AI, et al. Diarrheal illness and
 healthcare seeking behavior among a population at high risk for diarrhea in Dhaka,
 Bangladesh. PLOS ONE. 2015;10: e0130105. doi:10.1371/journal.pone.0130105
- 144. Fissehaye T, Damte A, Fantahun A, Gebrekirstos K. Health care seeking behaviour of
 mothers towards diarrheal disease of children less than 5 years in Mekelle city, North
 Ethiopia. BMC Res Notes. 2018;11: 749. doi:10.1186/s13104-018-3850-3
- 145. Luquero FJ, Rondy M, Boncy J, Munger A, Mekaoui H, Rymshaw E, et al. Mortality rates
 during cholera epidemic, Haiti, 2010–2011. Emerging Infectious Diseases. 2016;22.
 doi:10.3201/eid2203.141970
- 146. McCrickard LS, Massay AE, Narra R, Mghamba J, Mohamed AA, Kishimba RS, et al.
 Cholera mortality during urban epidemic, Dar es Salaam, Tanzania, August 16, 2015– January 16, 2016. Emerging Infectious Diseases. 2017;23. doi:10.3201/eid2313.170529
- 894 147. Watts V. Confidence intervals for a population proportion. 2022 [cited 10 Jul 2023].
 895 Available: https://ecampusontario.pressbooks.pub/introstats/chapter/7-4-confidenceintervals-for-a-population-proportion/
- 897
- 898 Tables
- 899 Table 1. Study characteristics
- 900 Number of observations included in the dataset with each study characteristic.

| Category | Characteristic | Number of | Percent of |
|----------|----------------|--------------|--------------|
| | | observations | observations |

| | | (n = 132) | |
|----------------------------|--------------------------|-----------|------|
| Study design | Surveillance | 93 | 70.5 |
| | Diagnostic test accuracy | 28 | 21.2 |
| | Vaccine effectiveness | 10 | 7.6 |
| | Randomized control trial | 1 | 0.8 |
| Sampling method quality | High | 37 | 28.0 |
| | Low | 95 | 72.0 |
| Percent of suspected cases | 0-4 | 12 | 9.1 |
| tested | 5-49 | 32 | 24.2 |
| | 50-95 | 27 | 20.5 |
| | ≥95 | 30 | 22.7 |
| | Not reported | 31 | 23.5 |
| Number of tests used (of | 1 | 106 | 80.3 |
| culture, PCR, and/or RDT)* | 2 | 19 | 14.4 |
| | ≥3 | 7 | 5.3 |
| Number of suspected cases | 1-9 [†] | 1 | 0.8 |
| tested | 10-99 | 37 | 28.0 |
| | 100-999 | 55 | 41.7 |
| | ≥1000 | 39 | 29.5 |

901 [†]One multi-country surveillance study overall tested ≥10 suspected cholera cases for

902 *V. cholerae* O1/O139 but reported fewer than 10 tested in one country.

903 *PCR = Polymerase Chain Reaction; RDT = Rapid Diagnostic Test

904

905 Figure legends

906 Figure 1. PRISMA flow diagram

- 907 Diagram illustrating literature selection process, including databases searched, literature
- screened, and full texts reviewed for eligibility. Reasons for exclusion are indicated along with
- 909 the number of studies that fell within each category.
- 910

911 Figure 2. *Vibrio cholerae* positivity by study methodology and outbreak context

912 Proportion of suspected cholera cases that were confirmed positive by A) diagnostic test type,

- **B)** quality of sampling methods, where "high" includes all suspected cases or a random or
- stratified sample and "low" includes convenience or unreported sampling methods, **C)** age
- 915 minimum in suspected case definition, where "0" indicates that no minimum age was set, and D)

916 whether surveillance was initiated in response to an outbreak or whether it was routine

- 917 surveillance or non-outbreak. Each point is an observation. Boxes represent the median and
- 918 interquartile range of positivity for each group. Lines extend from the top and bottom of box to

919 the largest positivity value no further than 1.5 * IQR from the box.

920

921 Figure 3. Estimated underlying *V. cholerae* positivity

922 A) Posterior distributions of pooled percent sensitivity and specificity of culture (top), PCR 923 (middle), and RDT (bottom) for detecting V. cholerae O1/O139 infections in suspected cholera 924 cases. Dashed lines represent mean values of each distribution. B) "Unadjusted" is mean V. 925 cholerae positivity (95% credible interval) from random effects meta-analysis without 926 adjustments for test performance. "Adjusted for test performance" is estimated mean V. 927 cholerae positivity (95% credible interval), adjusted for sensitivity/specificity of the tests. High-928 guality stratified estimates corresponds to post-stratified estimates of V. cholerae positivity for 929 studies that use high quality sampling methods and whether or not an age minimum was set in 930 the suspected case definition, as well as whether or not surveillance was initiated in response to 931 an outbreak.

932

933 Figure 4. Forest plot of study estimates and underlying positivity

- Black points indicate mean study-level underlying positivity and 95% Credible Interval (Crl).
- 935 Teal, orange, and purple points indicate the proportion positive reported by study for culture,
- 936 PCR, and RDT, respectively, and corresponding error bars indicate 95% confidence interval for
- 937 a binomial probability using the normal approximation [147]. Studies are labeled by country
- ISO3 code, whether they used high quality sampling methods, and whether a minimum age was
- 939 set in the suspected cholera case definition. Studies are split into outbreak and non-outbreak for
- 940 ease of interpretation.







Surveillance type





Non-outbreak surveillance

Outbreak surveillance

